Product
Epacadostat
Aliases
INCB024360, INCB 024360
16 clinical trials
39 indications
Indication
Renal Cell CarcinomaIndication
Head and Neck CancerIndication
Ovarian CancerIndication
GlioblastomaIndication
B-cell LymphomaIndication
Colorectal CancerIndication
lung cancerIndication
lymphomaIndication
MelanomaIndication
Metastatic Solid TumorsIndication
GliomaIndication
Pancreatic CancerIndication
Rectal CancerIndication
Fallopian Tube CancerIndication
Primary Peritoneal Cancer AJCC v7Indication
Stage IIIA Fallopian Tube Cancer AJCC v7Indication
Ovarian Cancer AJCC Stage IIIA v6 and v7Indication
Primary Peritoneal CancerIndication
Peritoneal CancerIndication
GISTIndication
Stomach AdenocarcinomaIndication
Esophageal CancerIndication
Esophageal carcinomaIndication
Recurrent Gastric CarcinomaIndication
Esophageal CarcinomaIndication
Ovarian clear cell carcinomaIndication
Recurrent Ovarian CarcinomaIndication
Prostate CancerIndication
Advanced Solid TumorIndication
Solid TumorIndication
Head and Neck Squamous Cell CarcinomaIndication
SarcomaIndication
fallopian tube carcinomaIndication
Primary Peritoneal CarcinomaIndication
NSCLCIndication
Gastric CancerClinical trial
A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)Status: Active (not recruiting), Estimated PCD: 2018-08-22
Clinical trial
A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)Status: Active (not recruiting), Estimated PCD: 2018-07-19
Clinical trial
A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)Status: Completed, Estimated PCD: 2020-06-16
Clinical trial
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2022-11-21
Clinical trial
Safety and Efficacy Study of Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent GliomasStatus: Active (not recruiting), Estimated PCD: 2024-07-19
Clinical trial
Phase 2 Study of Epacadostat, Pembrolizumab, and CRS-207, With or Without Cyclophosphamide and GVAX Pancreas Vaccine in Patients With Metastatic Pancreas CancerStatus: Active (not recruiting), Estimated PCD: 2023-08-22
Clinical trial
Study of Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal CancerStatus: Recruiting, Estimated PCD: 2027-07-15
Clinical trial
A Pilot Study of the Immunological Effects of Neo-Adjuvant INCB024360 in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CarcinomaStatus: Active (not recruiting), Estimated PCD: 2016-03-31
Clinical trial
A Phase II Study of Epacadostat and Pembrolizumab in Patients With Imatinib Refractory Advanced Gastrointestinal Stromal TumorsStatus: Terminated, Estimated PCD: 2020-08-19
Clinical trial
Phase 2 Study of Epacadostat (INCB024360) With Pembrolizumab (MK3475) in Metastatic or Unresectable Gastroesophageal Junction and Gastric Adenocarcinoma Requiring Paired BiopsiesStatus: Completed, Estimated PCD: 2018-05-29
Clinical trial
A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the OvaryStatus: Active (not recruiting), Estimated PCD: 2021-02-01
Clinical trial
A Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
The Trifecta Study: Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and EpacadostatStatus: Terminated, Estimated PCD: 2022-07-31
Clinical trial
Phase II Study of Epacadostat (INCB024360) in Combination With Pembrolizumab in Patients With Locally Advanced/Metastatic SarcomaStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
Phase I Study of Epacadostat (INCB24360) in Combination With Sirolimus in Advanced MalignancyStatus: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
A Phase I/IIb Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Combination With INCB024360 for Patients in Remission With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 AntigenStatus: Completed, Estimated PCD: 2020-08-20